Prostate Cancer Daily

June 17, 2026

Videos

Peer-to-Peer Clinical Conversations

How PSMA PET Restaging Reshapes the EMBARK High-Risk BCR Population - Alessandro Viti

Alessandro Viti

Alessandro Viti presents a retrospective cohort analysis comparing EMBARK-eligible patients staged with conventional imaging over nearly three decades against a modern cohort restaged with PSMA PET.

View

Radiopharmaceuticals in Prostate Cancer Part 4A: Endpoints, Immunotherapy, and Future Directions - Michael Morris & Rana McKay

Michael J. Morris

Michael Morris and Rana McKay discuss regulatory endpoints and emerging immunotherapy strategies in advanced prostate cancer with Philip Kantoff.

View

Beyond the Abstracts

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer - Beyond the Abstract

Prostate Cancer-Related Genetic Counseling in a Safety-Net Healthcare Setting - Beyond the Abstract

Conference Coverage

ASCO 2026: Real-World Overall Survival Outcomes of Lutetium (Lu177) Vipivotide Tetraxetan Treatment in Prostate Cancer

ASCO 2026: HRS-1167 (M9466), a PARP1 Inhibitor, Combined with Abiraterone Acetate and Prednisone in mCRPC: A Phase 1b/2 Study

ASCO 2026: ProTACT: Preliminary Data from a First-in-Human Phase 1 Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of [225Ac]Ac-FL-020, a PSMA-Targeted Radioconjugate, in Patients with mCRPC

ASCO 2026: Subgroup Analyses by Disease Volume and De Novo/recurrent mHSPC in the PSMAddition Study of [177Lu]Lu-PSMA-617

ASCO 2026: Canadian Cancer Trials Group (CCTG) Study PR21 (PLUDO): Results of Crossover Treatment from a Randomized Trial of 177Lu-PSMA-617 vs Docetaxel in Patients with mCRPC

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Development and validation of a digital pathology artificial intelligence (DPAI)-derived risk score predicting Gleason grade group reclassification for patients who are candidates for active surveillance.

da Vinci® single-port versus da Vinci® Xi multiport robot-assisted radical prostatectomy for localized prostate cancer: a GRADE-assessed systematic review and meta-analysis.

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy.

Limitations in diagnostics and quantification of small lesions with low uptake in the clinical context of prostate 18F/68Ga-PSMA PET/MRI.

International Delphi consensus on single-port robotic radical prostatectomy: patient selection, surgical technique, and training.

Bayesian re-analysis of ERA223 and PEACE-3 temporal dynamics and bone protection in radium-223-treated metastatic castration-resistant prostate cancer.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Prostate Cancer Daily

Prostate Cancer

Login